PMID- 31856374
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210914
IS  - 1744-9987 (Electronic)
IS  - 1744-9979 (Linking)
VI  - 24
IP  - 5
DP  - 2020 Oct
TI  - Esomeprazole vs pantoprazole effects on cyclosporine levels in kidney 
      transplantation: A randomized clinical trial.
PG  - 591-598
LID - 10.1111/1744-9987.13464 [doi]
AB  - Renal allograft survival requires multiple immunosuppressive drugs. This strategy 
      may lead to gastric complications that necessitate gastro-protective medications, 
      notably, proton pump inhibitors (PPI). This study aimed to compare the influence 
      of pantoprazole and esomeprazole on serum cyclosporine trough levels (C(0) ) in 
      renal transplant recipients (RTR). A prospective, parallel, open-label trial was 
      conducted on 47 adult RTR receiving cyclosporine doses adjusted to attain trough 
      concentrations of 100 to 150 mug/L, mycophenolate mofetil (MMF) 750 mg q12 hour 
      and prednisolone at 5 mg daily at Nasser Institute, Cairo, Egypt from January to 
      September 2016. Patients were randomized into the esomeprazole group (25) or 
      pantoprazole group (22) receiving the same dose (40 mg once daily). The study 
      outcomes included clinical signs of rejection and renal function decline, 
      assessed by elevations in serum creatinine, caused by cyclosporine level 
      variations in either of the two study groups. Renal function, C(0) and CBC 
      measurements were measured at baseline and monthly for 6 months. The mean C(0) 
      values were higher in the pantoprazole group than in the esomeprazole group in 
      the sixth month only (P = .007). Serum creatinine level was lower in the sixth 
      month than at baseline in the esomeprazole group (P = .004). There were no signs 
      of rejection biochemical or clinical in any of the study groups. In conclusion, 
      PPIs should be used with caution and doses should be titrated to reach the C(0) 
      targets in RTR, which is of more importance in pantoprazole than esomeprazole to 
      avoid C(0) level elevation or decline affecting the allograft function.
CI  - (c) 2019 International Society for Apheresis, Japanese Society for Apheresis, and 
      Japanese Society for Dialysis Therapy.
FAU - El-Bohy, Doaa
AU  - El-Bohy D
AUID- ORCID: 0000-0002-4283-9651
AD  - Department of Clinical Pharmacy, Future University in Egypt, Cairo, Egypt.
FAU - El Sharkawy, Magdy
AU  - El Sharkawy M
AD  - Department of Internal Medicine & Nephrology, Faculty of Medicine, Ain Shams 
      University, Cairo, Egypt.
FAU - Abo-Elazm, Soheir
AU  - Abo-Elazm S
AD  - Department of Pharmacology, Faculty of Medicine, Cairo University, Cairo, Egypt.
FAU - Shahin, Sara
AU  - Shahin S
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, 
      Cairo, Egypt.
FAU - Bchari, Waleed
AU  - Bchari W
AD  - Department of Internal Medicine & Nephrology, Faculty of Medicine, Ain Shams 
      University, Cairo, Egypt.
FAU - Mancy, Azza
AU  - Mancy A
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Fayoum University, Fayoum, 
      Egypt.
FAU - El Hamamsy, Manal
AU  - El Hamamsy M
AD  - Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, 
      Cairo, Egypt.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200123
PL  - Australia
TA  - Ther Apher Dial
JT  - Therapeutic apheresis and dialysis : official peer-reviewed journal of the 
      International Society for Apheresis, the Japanese Society for Apheresis, the 
      Japanese Society for Dialysis Therapy
JID - 101181252
RN  - 0 (Proton Pump Inhibitors)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - D8TST4O562 (Pantoprazole)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cyclosporine/*blood
MH  - Esomeprazole/blood/*pharmacology
MH  - Female
MH  - Humans
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Pantoprazole/blood/*pharmacology
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/blood/*pharmacology
MH  - Young Adult
OTO - NOTNLM
OT  - allograft rejection
OT  - cyclosporine
OT  - gastric complications
OT  - proton pump inhibitors
OT  - renal transplantation
EDAT- 2019/12/20 06:00
MHDA- 2021/09/15 06:00
CRDT- 2019/12/20 06:00
PHST- 2019/07/25 00:00 [received]
PHST- 2019/12/14 00:00 [revised]
PHST- 2019/12/17 00:00 [accepted]
PHST- 2019/12/20 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
PHST- 2019/12/20 06:00 [entrez]
AID - 10.1111/1744-9987.13464 [doi]
PST - ppublish
SO  - Ther Apher Dial. 2020 Oct;24(5):591-598. doi: 10.1111/1744-9987.13464. Epub 2020 
      Jan 23.